Pharma
Dr Reddys Laboratories Ltd
DRREDDY · NSE · INE089A01031Wednesday, 9 Sept 20263:16 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE8.8%
ROCE13.3%
ROE8.8%
1Y Return-3.74%
Avg. Volume1.5M
Price Chart
52-Week Range
About
Dr Reddys Laboratories Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,145.8
52W High / Low₹1,414.9 / ₹1,101
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE8.8%
1Y Return-3.74%
Day Change-0.50%
Profit & Loss
| Period | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Sales | ₹33,593 Cr | ₹32,554 Cr | ₹27,916 Cr | |
| Expenses | ₹28,581 Cr | ₹25,352 Cr | ₹21,386 Cr | |
| Operating Profit | ₹5,012 Cr | ₹7,201 Cr | ₹6,531 Cr | |
| OPM % | 14.9% | 22.1% | 23.4% | |
| Other Income | ₹1,358 Cr | ₹1,097 Cr | ₹228 Cr | |
| Depreciation | ₹2,061 Cr | ₹1,706 Cr | ₹1,484 Cr | |
| Interest | ₹374 Cr | ₹283 Cr | ₹171 Cr | |
| Profit Before Tax | ₹5,482 Cr | ₹7,678 Cr | ₹7,187 Cr | |
| Tax | ₹1,235 Cr | ₹1,954 Cr | ₹1,619 Cr | |
| Net Profit | ₹4,247 Cr | ₹5,725 Cr | ₹5,568 Cr | |
| EPS (₹) | 51.4 | 67.8 | 66.9 | |
| Dividend Payout % | — | — | — |
Financial history locked
Register freeRegister free to see 1 more year.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Sales | ₹8,071 Cr | ₹7,516 Cr | ₹8,727 Cr | ₹8,545 Cr |
| Expenses | ₹7,767 Cr | ₹7,433 Cr | ₹7,294 Cr | ₹6,861 Cr |
| Operating Profit | ₹303 Cr | ₹83 Cr | ₹1,433 Cr | ₹1,684 Cr |
| OPM % | 3.8% | 1.1% | 16.4% | 19.7% |
| Depreciation | ₹537 Cr | ₹558 Cr | ₹521 Cr | ₹477 Cr |
| Interest | ₹126 Cr | ₹106 Cr | ₹94 Cr | ₹83 Cr |
| Net Profit | ₹435 Cr | ₹221 Cr | ₹1,190 Cr | ₹1,410 Cr |
| EPS (₹) | 5.3 | 2.7 | 14.5 | 17.0 |
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹84 Cr | ₹83 Cr | ₹83 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹37,623 Cr | ₹33,255 Cr | ₹27,972 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹7,734 Cr | ₹4,677 Cr | ₹2,002 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹12,494 Cr | ₹11,283 Cr | ₹8,695 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹57,935 Cr | ₹49,299 Cr | ₹38,752 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹11,593 Cr | ₹9,776 Cr | ₹7,689 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,637 Cr | ₹1,520 Cr | ₹526 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹10,122 Cr | ₹9,042 Cr | ₹8,030 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹7,653 Cr | ₹7,109 Cr | ₹6,355 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹1,537 Cr | ₹1,465 Cr | ₹711 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹25,393 Cr | ₹20,387 Cr | ₹15,442 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹57,935 Cr | ₹49,299 Cr | ₹38,752 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 1 more year.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹5,676 Cr | ₹-6,551 Cr | ₹829 Cr | ₹-47 Cr |
| FY25 | ₹4,643 Cr | ₹-5,808 Cr | ₹1,891 Cr | ₹726 Cr |
| FY24 | ₹4,543 Cr | ₹-4,028 Cr | ₹-376 Cr | ₹139 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 1 more year.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
| Max Healthcare Institute Ltd | ₹1,00,553 Cr | 67.2 | +14.7% | +0.87% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.